Inozyme Pharma, Inc. (NASDAQ:INZY – Get Free Report) was the target of a large growth in short interest in June. As of June 30th, there was short interest totalling 4,130,000 shares, a growth of 51.3% from the June 15th total of 2,730,000 shares. Based on an average daily volume of 468,600 shares, the short-interest ratio is currently 8.8 days. Currently, 9.9% of the company’s stock are sold short.
Inozyme Pharma Stock Up 3.1 %
Shares of NASDAQ:INZY traded up $0.16 during trading on Monday, hitting $5.31. 108,755 shares of the company were exchanged, compared to its average volume of 513,300. The stock has a market cap of $328.46 million, a price-to-earnings ratio of -3.88 and a beta of 1.53. Inozyme Pharma has a fifty-two week low of $2.69 and a fifty-two week high of $7.80. The firm has a fifty day moving average price of $4.63 and a two-hundred day moving average price of $5.11. The company has a current ratio of 14.05, a quick ratio of 14.05 and a debt-to-equity ratio of 0.38.
Inozyme Pharma (NASDAQ:INZY – Get Free Report) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.03). As a group, research analysts anticipate that Inozyme Pharma will post -1.59 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Get Our Latest Stock Report on INZY
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the stock. Values First Advisors Inc. bought a new position in shares of Inozyme Pharma during the 4th quarter worth approximately $59,000. SG Americas Securities LLC boosted its stake in shares of Inozyme Pharma by 46.9% during the 4th quarter. SG Americas Securities LLC now owns 21,236 shares of the company’s stock worth $90,000 after acquiring an additional 6,784 shares during the period. Superstring Capital Management LP bought a new position in shares of Inozyme Pharma during the 4th quarter worth approximately $528,000. Kennedy Capital Management LLC boosted its stake in shares of Inozyme Pharma by 52.2% during the 1st quarter. Kennedy Capital Management LLC now owns 437,657 shares of the company’s stock worth $3,352,000 after acquiring an additional 150,120 shares during the period. Finally, Affinity Asset Advisors LLC boosted its stake in shares of Inozyme Pharma by 36.7% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,885,802 shares of the company’s stock worth $8,034,000 after acquiring an additional 505,950 shares during the period. Institutional investors and hedge funds own 88.30% of the company’s stock.
Inozyme Pharma Company Profile
Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.
Featured Stories
- Five stocks we like better than Inozyme Pharma
- What is a Dividend King?
- Automaker’s Bold Move to an EV Future: Is It Time to Buy Stock?
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Massive Breakout: This ETF Signals Big Gains for Small-Cap Stocks
- P/E Ratio Calculation: How to Assess Stocks
- Major Gaming Stock to Watch: Why It’s a Safe Bet Now
Receive News & Ratings for Inozyme Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inozyme Pharma and related companies with MarketBeat.com's FREE daily email newsletter.